The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review.
Chloroquine and hydrocychloroquine have been evaluated in 30 noninfectious disorders and conditions other than rheumatoid arthritis or lupus erythematosus; 12 of these have been subjected to well-designed controlled trials. It is concluded that chloroquines are safe and effective first line therapies for selected patients with porphyria cutanea tarda, cutaneous sarcoidosis, cutaneous manifestations of dermatomyositis, hyperlipidemias and thromboembolic prophylaxis for patients with antiphospholipid antibodies. Published experience with these and other diseases or syndromes are critically reviewed.
Wallace
D J
DJ
Cedars-Sinai Medical Center/UCLA School of Medicine, USA.
D000962:Antimalarials / Q000627:therapeutic use*; D016736:Antiphospholipid Syndrome / Q000188:drug therapy; D001327:Autoimmune Diseases / Q000188:drug therapy; D002738:Chloroquine / Q000627:therapeutic use*; D018849:Controlled Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000188:drug therapy; D017119:Porphyria Cutanea Tarda / Q000188:drug therapy; D012507:Sarcoidosis / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy; D013923:Thromboembolism / Q000517:prevention & control
D000962:Antimalarials; D006886:Hydroxychloroquine; D002738:Chloroquine